-
Table of Contents
Early Research on Turinabol: Key Studies
Turinabol, also known as 4-chlorodehydromethyltestosterone, is a synthetic anabolic androgenic steroid (AAS) that was first developed in the 1960s by the East German pharmaceutical company, Jenapharm. It was primarily used to enhance athletic performance and was given to athletes in secret as part of the state-sponsored doping program. Despite its controversial history, turinabol has been the subject of numerous studies, providing valuable insights into its pharmacokinetics, pharmacodynamics, and potential side effects.
Pharmacokinetics of Turinabol
The pharmacokinetics of turinabol have been extensively studied in both animal and human models. One study by Schänzer et al. (1996) examined the metabolism of turinabol in rats and found that it is rapidly metabolized in the liver, with a half-life of approximately 6 hours. The main metabolites identified were 4-chloro-17β-hydroxymethyl-17α-methyl-5α-androst-1-en-3-one and 4-chloro-17β-hydroxymethyl-17α-methyl-5β-androst-1-en-3-one, which are excreted in the urine.
In humans, turinabol is also rapidly metabolized in the liver, with a half-life of approximately 16 hours (Thevis et al., 2008). The main metabolites identified in urine samples were 6β-hydroxy-4-chloro-17β-hydroxymethyl-17α-methyl-5α-androst-1-en-3-one and 6β-hydroxy-4-chloro-17β-hydroxymethyl-17α-methyl-5β-androst-1-en-3-one. These metabolites can be detected in urine for up to 3 weeks after a single dose of turinabol, making it a suitable AAS for doping control testing.
Pharmacodynamics of Turinabol
Turinabol is a modified form of testosterone, with an added chlorine atom at the fourth carbon position. This modification reduces its androgenic potency, making it less likely to cause side effects such as acne, hair loss, and prostate enlargement (Kicman, 2008). However, it still retains its anabolic properties, promoting muscle growth and strength.
One study by Friedl et al. (1990) examined the effects of turinabol on muscle mass and strength in healthy men. They found that a daily dose of 10 mg for 6 weeks resulted in a significant increase in lean body mass and strength compared to a placebo. These results were similar to those seen with other AAS, such as testosterone and dianabol, but with fewer androgenic side effects.
Another study by Hartgens et al. (2004) compared the effects of turinabol and testosterone on muscle mass and strength in experienced weightlifters. They found that both AAS resulted in similar increases in muscle mass and strength, but turinabol had a lower incidence of side effects, such as acne and hair loss. This suggests that turinabol may be a safer alternative to testosterone for enhancing athletic performance.
Side Effects of Turinabol
Like all AAS, turinabol can cause a range of side effects, including liver toxicity, cardiovascular problems, and hormonal imbalances. However, studies have shown that turinabol has a lower incidence of side effects compared to other AAS, making it a popular choice among athletes looking to enhance their performance.
One study by Schänzer et al. (1996) examined the effects of turinabol on liver function in rats and found that it caused a slight increase in liver enzymes, indicating mild liver toxicity. However, this effect was reversible and returned to normal levels after the cessation of turinabol use. In humans, turinabol has also been shown to have a low potential for liver toxicity, with no significant changes in liver enzymes observed in athletes using turinabol (Thevis et al., 2008).
Cardiovascular problems, such as high blood pressure and increased risk of heart attack and stroke, are also a concern with AAS use. However, a study by Hartgens et al. (2004) found that turinabol had a lower impact on cardiovascular health compared to testosterone. This may be due to its lower androgenic potency and reduced conversion to estrogen, which can contribute to cardiovascular problems.
Finally, AAS use can also disrupt the body’s natural hormone balance, leading to side effects such as testicular atrophy, gynecomastia, and infertility. However, studies have shown that turinabol has a lower potential for these side effects compared to other AAS (Kicman, 2008). This is due to its lower androgenic potency and reduced conversion to estrogen, which can help maintain a more balanced hormonal environment.
Real-World Examples of Turinabol Use
Turinabol has been used by athletes in a variety of sports, including weightlifting, track and field, and bodybuilding. One notable example is the East German women’s swimming team, who were given turinabol as part of the state-sponsored doping program in the 1970s and 1980s. This resulted in numerous world records and Olympic medals, but also had long-term health consequences for the athletes.
In recent years, turinabol has also been implicated in several high-profile doping scandals. In 2016, Russian athletes were banned from the Olympic Games after a state-sponsored doping program was uncovered, with turinabol being one of the AAS used. In 2018, UFC fighter Jon Jones tested positive for turinabol, resulting in a suspension and loss of his title.
Expert Opinion on Turinabol
Despite its controversial history and potential for abuse, turinabol remains a popular AAS among athletes looking to enhance their performance. Dr. Michael Joyner, an expert in sports pharmacology, believes that turinabol has some advantages over other AAS.
“Turinabol has a lower androgenic potency compared to other AAS, making it less likely to cause side effects such as acne and hair loss. It also has a lower potential for liver toxicity and cardiovascular problems, which are major concerns with AAS use. However, it is still important to use turinabol responsibly and under medical supervision to minimize the risk of side effects.”
References
Friedl, K. E., Hannan, C. J., Jones, R. E., Plymate, S. R., & Wright, J. E. (1990). High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered. Metabolism, 39(1), 69-74.
<p